Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma

Neuro-Oncology

Volumn 15, Issue 6, 2013, Pages 727-734

  He, Miaoxia ^a   Zuo, Changjing ^a   Wang, Jianjun ^a   Liu, Jianmin ^a   Jiao, Binghua ^b   Zheng, Jianmin ^a   Cai, Zailong ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

central nervous system; diffuse large B cell lymphoma; histopathology; prognosis

Indexed keywords

HERMES ANTIGEN; METHOTREXATE; X BOX BINDING PROTEIN 1;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL AGGREGATION; CELL GROWTH; CELL INFILTRATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR CELL;

CENTRAL NERVOUS SYSTEM; DIFFUSE LARGE B-CELL LYMPHOMA; HISTOPATHOLOGY; PROGNOSIS;

ADULT; AGED; ANIMALS; ANTIGENS, CD44; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PERIVASCULAR EPITHELIOID CELL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878298292     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not012     Document Type: Article

References (34)

1. Louis DN, Ohgaki H, Wiestler OD, et al. World Health Organization Classification of Tumors of the Central Nervous System. Lyon: IARC Press 2007.
2. Hagavathi S, Sharathkumar A, Hunter S, et al. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clin Neuropathol. 2008; 27: 13-20.
3. Li J, Okamoto H, Yin C, et al. Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system. J Neurosurg. 2008; 109: 536-546.
4. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours: Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.
5. Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med. 2008; 122: 1830-1834.
6. Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not?. Blood. 2009; 113: 7-10.
7. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin's lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002; 95: 1504-1510.
8. Dubuisson A, Kaschten B, Lénelle J, et al. Primary central nervous system lymphoma report of 32 cases and review of the literature. Clin Neurol Neurosurg. 2004; 107: 55-63.
9. Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006; 107: 3716-3723.
10. D'Haene N, Catteau X, Maris C, et al. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br J Haematol. 2008; 140: 402-410.
11. Kadoch C, Dinca EB, Voicu R, et al. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009; 15: 1989-1997.
12. Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology. 2011; 58: 69-80.
13. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal, Lymphoma Study Group experience. J Clin Oncol. 2003; 21: 266-272.
14. Tótth AA, Schnur J, Ladányi A, et al. Intracerebral human lymphoma - an experimental model. Pathol Oncol Res. 1996; 2: 174-176.
15. He MX, Wang JJ, Zhou XP, et al. Development of a nude mouse model for diffuse large B-cell lymphoma of brain. Zhonghua Bing Li Xue Za Zhi. 2011; 40(12): 840-842. Article in Chinese.
16. Ponzoni M, Berger F, Chassagne-Clement C, et al. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol. 2007; 138: 316-323.
17. Kumari N, Krishnani N, Rawat A, et al. Primary central nervous system lymphoma: Prognostication as per international extranodal lymphoma study group score and reactive CD3 collar. J Postgrad Med. 2009; 55: 247-251.
18. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in nodenegative breast cancer. J Natl Cancer Inst. 1993; 85: 200-206.
19. O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer. Hum Pathol. 1996; 27: 955-963.
20. Romero-Ramirez L, Cao H, Nelson D, et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 2004; 64: 5943-5947.
21. Fujimoto T, Onda M, Nagai H, et al. Upregulation and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer. 2003; 10: 301-306.
22. Iwakoshi NN, Lee AH, Vallabhajosyula P, et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003; 4: 221-229.
23. Maestre L, Tooze R, Canamero M, et al. Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica. 2009; 94: 419-422.
24. Rubenstein JL, Shen A, Batchelor TT, et al. Differential gene expression in central nervous system lymphoma. Blood. 2009; 113: 266-267.
25. Mempel TR, Marangoni F. CD44 keeps tumor killers polarized. Immunity. 2008; 29: 843-845.
26. Naor D, Wallach-Dayan SB, Zahalka MA, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol. 2008; 18: 260-267.
27. Kim YS, Seo DW, Kong SK, et al. TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/ post-germinal center B cell differentiation. Cancer Lett. 2008; 269: 37-45.
28. Eberth S, Schneider B, Rosenwald A, et al. Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer. 2010; 10: 517.
29. Ferreri AJ, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin N Am. 2005; 19: 629-649.
30. Ferreri AJ, Reni M, Pasini F, et al. A multicentre study of treatment of primary CNS lymphoma. Neurology. 2002; 58: 1513-1520.
31. Aho R, Ekfors T, Haltia M, et al. Pathogenesis of primary central nervous system lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyme. Acta Neuropathol (Berl). 1993; 86: 71-76.
32. Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood. 2008; 111: 2200-2210.
33. Brunn A, Montesinos-Rongen M, Strack A, et al. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol. 2007; 114: 271-276.
34. Bessell EM, Hoang-Xuan K, Ferreri AJ, et al. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer. 2007; 43: 1141-1152.